-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to news from the Chinese Academy of Sciences website and the Chinese Academy of Engineering website on November 18, the results of the co-election of academicians of the two academies in 2021 were officially announced.
Xu Binghe, male, born in February 1958, chief physician, professor, and doctoral supervisor
"Don't treat advanced breast cancer as terminal disease
Xu Binghe focuses on cutting-edge theories and technical research in the field of breast cancer, and leads the team to make a series of pioneering research work in breast cancer screening and early diagnosis, individualized treatment, and tumor resistance.
The pyrrotinib he took the lead in research and development is China's first approved domestically-developed innovative drug HER-2 small molecule inhibitor, breaking the long-term monopoly of HER-2 targets by imported drugs and creating a precedent for rapid approval of clinical trials for marketing
In the past five years, he has led the completion of China’s first approved listing of CDK4/6 inhibitor piperacillil, the first domestically produced CDK4/6 drug SHR6390, the first breast cancer ADC drug TDM-1, and the first China-Europe dual-reported domestic product.